Tag Archives: Codiak BioSciences

Codiak BioSciences a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated...

Codiak BioSciences, a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) for ...

Codiak BioSciences, a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines...

PODs Will Support Clinical Manufacturing for this Novel Therapeutic Modality. G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, announced today that it has been selected by Codiak BioSciences to support its cleanroom build out at its new clinical manufacturing ...

Alliance to explore the utility of engineered exosomes developed with Codiak’s engEx™ Platform to deliver gene therapy, gene editing and RNA technologies – – Two-year, global research and option...

Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the ...

Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced new preclinical...

exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12 exoSTING shows unique pharmacodynamic effects and tumor antigen-specific systemic immune responses.

  In vitro and in vivo profile of exoSTING showed greater potency, preservation of T cells and APCs, greater systemic tumor antigen specific immune response, reduced systemic cytokine production, and enhanced anti-tumor immunity compared to free STING agonist Codiak’s PTGFRN ...

Collaboration strengthens Jazz portfolio with novel therapeutic approach that has potential to provide transformational benefit to subgroup of patients with modulations in well validated but previously...